DENVER–(BUSINESS WIRE)–#BIOCEO–TriSalus Life Sciences, a company committed to developing comprehensive solid tumor solutions, today announced that Mary Szela, President and CEO, will speak on the panel, “Expanding the Toolkit for Fighting Solid Tumors” at the 2020 BIO CEO & Investor Conference in New York City.
This panel will explore the breadth of the solid tumor-fighting pipelines and those clinical benefits likely to be realized soonest. Experience has shown that to date there has been limited success with the currently approved or experimental therapeutics in impacting solid tumors and that these often have undesirable side effects. While we have witnessed a surge of systemic therapies in recent years (For example, the check point inhibitors), the need for safer and truly effective treatment remains.
However, exciting approaches in other mechanisms of action are also expanding our understanding of solid tumors, the tumor microenvironments, and the opportunities to disrupt tumor growth and help cancer patients. “I am honored to participate in such an important panel discussion of how we can improve outcomes in solid tumors through new approaches such as TriSalus’ tri-pronged approach which combines CAR-T with an immuno-modulation agent and proprietary, intravascular delivery to treat liver metastases and pancreatic cancer,” said Mary Szela, President and CEO of TriSalus.
Now in its 22nd year, the BIO CEO & Investor Conference is one of the largest independent investor conferences focused on established and emerging publicly traded and select private biotech companies including two days of productive partnering meetings with institutional and early-stage investors, industry analysts, and senior biotechnology executives, in one location.
Mary has limited availability during the conference. If you are interested in setting up a meeting with Mary, please contact Lisa DeScenza from LaVoieHealthScience at ldescenza@lavoiehealthscience.com.
About TriSalus Life Sciences
TriSalus Life Sciences is dedicated to improving patient outcomes in pancreatic and other highly intractable solid tumors. TriSalus’ tri-pronged approach has the potential to deliver novel therapeutic agents and immuno-stimulants directly into a tumor’s vasculature using its proprietary Pressure-Enabled Drug Delivery™ (PEDD™) approach to improve the distribution and penetration of therapy in solid tumors. This innovative approach has the potential to allow for the administration of multiple mechanisms that can work together to overcome inherent immune suppression within the solid tumor microenvironment, maximize drug penetration, and decrease systemic side effects. For more information, please visit www.trisaluslifesci.com.
Contacts
TriSalus Media Contact:
Emmie Twombly
Media Specialist
LaVoieHealthScience
(857) 389-6042
etwombly@lavoiehealthscience.com
TriSalus Investor Contact:
Lisa DeScenza
Vice President, Integrated Communications
LaVoieHealthScience
(978) 395-5970
ldescenza@lavoiehealthscience.com